Navigation Links
New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis
Date:9/3/2008

from select studies include the following:

New Treatment Pathways

A study led by Dr. Gary S. Firestein at the University of California

School of Medicine, San Diego focuses on how the central nervous system

can control inflammation in RA. The group identified a new pathway that

allows the spinal cord and brain to decrease joint inflammation and joint

destruction. Now that this pathway is identified, new therapies can be

developed to utilize it and mimic the anti-inflammatory effects of the

central nervous system.

Early Detection of RA

Successful management of RA requires early medical intervention and a new

study led by Dr. Antony Rosen at the Johns Hopkins University School of

Medicine seeks to identify specific pathways that drive RA development and

generate tissue damage. Dr. Rosen and his team of researchers are working

to define new blood tests to help rheumatologists diagnose RA in its early

stages, which will improve their ability to predict which patients will

develop worse joint destruction, and potentially provide the tools to

monitor disease activity and prevent early RA from amplifying.

Health Literacy and Patient-Physician Interaction

Dr. Edward Yelin and Dr. Jennifer Barton of the University of California,

San Francisco are leading the most systematic attempt to understand the

role that patient-physician communication and health literacy play in

understanding disparities in RA treatment and healthcare outcomes for

different patient populations. This study compares standard measures of

disease activity such as degree of joint damage, with assessments of

socioeconomic status such as income, education level and employment

status, race/ethnicity of the patient and the language spoken at home to

explain disparities in care and treatment of RA.

About Within Our Reach: Finding a Cure
'/>"/>

SOURCE ACR Research and Education Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the ... direct oral once-daily Factor Xa inhibitor, significantly reduced the ... or hip arthroplasty, when compared to enoxaparin. Patients receiving ... deep vein thrombosis (DVT) and pulmonary embolism (PE) than ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), ... outsourcing company with operations in China and the United ... Science and Chemistry Awards, held on December 12, 2011 ... theme of this year,s awards was Disease Biology. Guowei ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
(Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A ... & Schulte LLC to provide consumers with the most ... accompany use of the blood-thinning medication, as well as ... pending in courts around the country. The law firm ... may have suffered from life-threatening internal bleeding and related ...
(Date:7/13/2014)... July 13, 2014 According to The ... is a comprehensive program that teaches people how to ... neuropathy without medications. This program also provides people ... of peripheral neuropathy , including numbness, prickling, burning, and ... review that this home treatment program can help people ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, iFitDress.com, one ... new selection of red evening gowns . What’s more, ... to 56% off. , The company’s senior spokesman states, “We ... shopping on our website is an enjoyable shopping experience. In ... In our online store, low prices do not always mean ...
Breaking Medicine News(10 mins):Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
... Molecular Immunologist and his team has found a new virus ... inflammation and autoimmune diseases. The new delivery system acts as ... virus containing the required genes are transferred into the T ... the immune cells they get attracted towards the cancer cell ...
... experience 25% less muscle and joint pain in their old ... has also revealed that people who regularly participate in // ... non-runners even though they are more likely to suffer from ... the level of pain in a group of runners and ...
... on many issues, however one issue that is likely// to ... poor Pakistani children later this month for heart treatment. ... many more similar gestures and result in a harmony between ... border have failed to deliver in the last 50 years. ...
... Trading is responsible for checking the profits and safety ... NHS. They have to monitor that only branded and ... reasonable. ,The Pharmaceutical Price Regulation Scheme [PPRS] ... agreement of the pricing and quality of the drugs ...
... Research suggests that the patients of multiple sclerosis (MS) ... at risk from it. ,Although treatment with interferon ... damage in the brains of patients with multiple sclerosis ... called black holes, on magnetic resonance imaging (MRI), treatment ...
Cached Medicine News:Health News:Surgeons in India to Mend ‘Pakistani Hearts’ by treating 70 Childr 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Patients Of MS Are Not At Risk From The Interferon Treatment 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: